Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Background No treatment options are available for patients with metastatic colorectal cancer
that progresses after all approved standard therapies, but many patients maintain a good …
that progresses after all approved standard therapies, but many patients maintain a good …
Regorafenib for patients with metastatic colorectal cancer who progressed after standard therapy: results of the large, single‐arm, open‐label phase IIIb CONSIGN …
E Van Cutsem, E Martinelli, S Cascinu… - The …, 2019 - academic.oup.com
Background In the phase III CORRECT trial, regorafenib significantly improved survival in
treatment‐refractory metastatic colorectal cancer (mCRC). The CONSIGN study was …
treatment‐refractory metastatic colorectal cancer (mCRC). The CONSIGN study was …
[HTML][HTML] Safety and effectiveness of regorafenib in patients with metastatic colorectal cancer in routine clinical practice in the prospective, observational CORRELATE …
M Ducreux, LN Petersen, L Öhler, F Bergamo… - European Journal of …, 2019 - Elsevier
Background Regorafenib prolonged overall survival (OS) versus placebo in patients with
treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an …
treatment-refractory metastatic colorectal cancer (mCRC) in phase III trials. We conducted an …
Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a …
A Adenis, C de la Fouchardiere, B Paule, P Burtin… - BMC cancer, 2016 - Springer
Background Randomized trials have shown a survival benefit for regorafenib over placebo
in patients with metastatic colorectal cancer (mCRC) that progressed after standard …
in patients with metastatic colorectal cancer (mCRC) that progressed after standard …
Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations
T Yoshino, Y Komatsu, Y Yamada, K Yamazaki… - Investigational new …, 2015 - Springer
Background In the international, phase III, randomized, double-blind CORRECT trial,
regorafenib significantly prolonged overall survival (OS) versus placebo in patients with …
regorafenib significantly prolonged overall survival (OS) versus placebo in patients with …
Regorafenib: a review in metastatic colorectal cancer
S Dhillon - Drugs, 2018 - Springer
Regorafenib (Stivarga®) is an oral small-molecule multiple kinase inhibitor. It is indicated
worldwide for patients with metastatic colorectal cancer (mCRC). In the EU and USA it is …
worldwide for patients with metastatic colorectal cancer (mCRC). In the EU and USA it is …
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a …
Background In the international randomised phase 3 CORRECT trial (NCT01103323),
regorafenib significantly improved overall survival versus placebo in patients with treatment …
regorafenib significantly improved overall survival versus placebo in patients with treatment …
Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
D Strumberg, ME Scheulen, B Schultheis… - British journal of …, 2012 - nature.com
Background: In a phase I dose-escalation study, regorafenib demonstrated tolerability and
antitumour activity in solid tumour patients. The study was expanded to focus on patients …
antitumour activity in solid tumour patients. The study was expanded to focus on patients …
Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study
Background Regorafenib confers an overall survival benefit in patients with refractory
metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its …
metastatic colorectal cancer; however, the adverse event profile of regorafenib has limited its …
Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus …
LBA385 Background: Regorafenib (BAY 73-4506) is an oral multikinase inhibitor of a broad
range of angiogenic, oncogenic, and stromal kinases. The phase III CORRECT trial was …
range of angiogenic, oncogenic, and stromal kinases. The phase III CORRECT trial was …